Navigation Links
Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
Date:5/16/2008

59

income 57,936 455,801

Interest income, net -- (927,054)

Amortization of debt discount

and financing costs

Interest expense on convertible

notes -- (255,309)

Net Loss $(2,537,419) $(29,342,424)

Basic and Diluted Net Loss Per

Common Share $(0.15)

Basic and Diluted Weighted

Average Number of Common

Shares Outstanding 16,732,003

SENESCO TECHNOLOGIES, INC. AND SUBSIDIARY

(A DEVELOPMENT STAGE COMPANY)

CONDENSED CONSOLIDATED BALANCE SHEETS

March 31, June 30,

2008 2007

(unaudited)

ASSETS

CURRENT ASSETS:

Cash and cash equivalents $4,049,233 $408,061

Short-term investments 500,000 250,000

Prepaid expenses and other current assets 57,695 104,526

Total Current Assets 4,606,928 762,587

Property and equipment, net 6,880 7,526

Intangibles, net 3,032,449 2,544,447

Deferred financing costs 729,029 --

Security deposit 7,187 7,187

TOTAL ASSETS $8,382,473 $3,321,747

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:

Accounts payable $168,525 $109,258

Accrued expenses 509,619 377,359

Deferred revenue
'/>"/>

SOURCE Senesco Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
2. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
3. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
4. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
5. Adnavance Technologies Inc. Appoints Christian P. Valcke, Ph.D., to Its Scientific Advisory Board
6. Sturgeon and Caviar From Aquaculture: United Food Technologies AG Hands Over Turnkey Plant
7. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
8. Veran Medical Technologies Secures $4.75M in First Institutional Funding
9. Neurobiological Technologies Reports Third Quarter Financial Results
10. InSet Technologies Appoints Jon Tremmel to its Board of Directors
11. Applied Isotope Technologies will Exclusively Supply Biochemimarker(TM) Discovery Products for a Unique Pilot Study on Autism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 Mapp Biopharmaceutical,s valiant effort to ... to fight the Ebola outbreak will make the ... production of pharmaceuticals can be, according to Kalorama ... while some may be taken aback by the ... industry knowledge are well aware of the complex ...
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... , October 20, 2014 , ... (GI) disorders and the delivery of care has revealed ... and worrying inequalities in the provision of healthcare services ... was commissioned by United European Gastroenterology (UEG), have been ... and public awareness of the burden of GI disorders ...
(Date:10/20/2014)... PureTech , a science and technology development ... today the closing of a $55 million growth ... a $120 Billion group of funds. The funding ... forward and to advance new healthcare related products ... really go for the big ideas that can ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... Jennerex, Inc. (San Francisco), a clinical-stage cancer ... Burke, M.D. to the newly-created position of vice president, ... global clinical research activities related to Jennerex pipeline compounds. ... Jennerex in an advisory capacity as a clinical advisor ...
... This release is available in French . ... a huge amount of groundwater pollution worldwide, and this has had ... Lollar, Canada Research Chair in Isotope Geochemistry of the Earth and ... is taking part in the THINK CANADA Press Breakfast Sunday at ...
... range of benefits over traditional materials and enables ... there are often concerns about the safety aspects ... High-quality measurements are the basis for reliable safety ... of new nanotechnology applications. , Until now, ...
Cached Biology Technology:Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research 2Water, water, everywhere... but is it safe to drink? 2First certified reference material for nanoparticle size analysis 2First certified reference material for nanoparticle size analysis 3
(Date:10/16/2014)... respiratory tract infections and worldwide claims the lives ... and Ghent University have succeeded in developing a ... infection. , Xavier Saelens (VIB/UGent): "We discovered ... for the development of a novel approach to ... in numerous small children and elderly people." , ...
(Date:10/15/2014)... As our ability to assess the pandemic risk from ... developments, we must not allow ourselves to become complacent ... an international consortium of scientists. , Influenza pandemics arise ... have yet to develop widespread immunity – spreads in ... in the past 100 years, the worst of which ...
(Date:10/15/2014)... in female mice to an enzyme activated by the ... resistant to respiratory infections than males. Now, an international ... bacterial pneumonia in female mice is linked to the ... that this enzyme is ultimately activated by the release ... lead by Professor Lester Kobzik at the Harvard University ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... the Vanderbilt greenhouse held more members of a rare ... in the wild., This unusual bounty was the result ... student in the biological sciences department, working under the ... called the giant whorled sunflower, Helianthus verticillatus. It was ...
... Cryptochromes, which fulfill the molecular requirements for sensing the ... neurons of migratory birds (Mouritsen et al., PNAS, 2004). ... brain are active when the birds use their magnetic ... and a forebrain region (Cluster N; Mouritsen et al., ...
... world-renowned expert on bird speciation has compiled eight ... published book, Speciation in Birds. Trevor Price, ... the contributions of sexual selection and natural selection ... isolation, ecological differentiation and genetic drift. He discusses ...
Cached Biology News:Student study bolsters case for adding a rare sunflower to the endangered species list 2University biologist publishes book on bird speciation 2
Request Info...
The Cellject Elecroporator is suitable for all cell types including embryo, mammalian, plant, yeast and bacterial. Its has highly user-freindly programing and can be used remotely, for example in a l...
Maxi 14 Hybridization Oven. 14 bottle (35 mm) rotisserie + shaker tray available for simultaneous use. Includes linear and orbital shaker trays, 4 medium bottles, pack of mesh, bottle gripper and d...
... The Neural Stem Cell Expansion Kit - Monolayer ... NSC expansion as a monolayer in a ... N-2 Plus Media Supplement, which has been optimized ... et al . (1996) Genes & Development ...
Biology Products: